Insider trade

Biogen (BIIB): Head of Development received 11K units

Priya Singhal, Head of Development at Biogen, reported a grant / award of 11K units.

11K
Derivative units
Traded
Feb 13, 2026
Filed
Feb 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 13, 2026Company filing · Form 8-K · ResultsReported its results
  2. Jan 30, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  3. Feb 2, 2026InsiderOfficer sold ~$134K of BIIB shares in the open market
  4. Feb 5, 20265% stakeFMR LLC reported a passive stake (13G) of 6.4%
  5. Feb 6, 2026Company filing · Form 8-K · ResultsReported its results
  6. Feb 9, 2026InsiderOfficer sold ~$532K of BIIB shares in the open market
  7. Feb 11, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. (“Biogen” or the “Company”) Board of Directors (the “Board”) announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
  8. Feb 12, 2026Insider · Their first buy on recordOfficer purchased ~$585 of BIIB shares in the open market

What came next

  1. Mar 11, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026.”
  2. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  3. Mar 27, 2026FDAFDA drug approval: Spinraza
  4. Mar 31, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  5. Apr 6, 2026Company filing · Form 8-K · ResultsReported its results
  6. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  7. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  8. May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 8.7%
  9. May 11, 2026Congress · 1 personMembers of Congress: 2 purchases
  10. May 12, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  11. May 14, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“Pursuant to the Merger Agreement, on April 14, 2026, Purchaser commenced a tender offer (the “Offer”) to acquire any and all of the issued and outstanding Shares, in exchange for (i) $41.00 per Share, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the “Cash Amount”), plus (ii) one contractual, non-transferable contingent value right per Share (each, a “CVR”)…”
  12. Jun 5, 20265% stakeFMR LLC reported a passive stake (13G) of 11.3%
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Biogen

For Biogen, OQRO holds 2 Congress trade reports dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BIIB page.

Other recent filings by Priya Singhal, Head of Development

The full history of Priya Singhal, Head of Development is on the profile page.

How this filing works

Explore the data

Common questions

Which Biogen (BIIB) insider traded, and how much?

Priya Singhal, Head of Development at Biogen, reported a grant / award of 11K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Feb 13, 2026. Filed: Feb 18, 2026. That is 5 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Biogen recently?

For Biogen, OQRO holds 2 Congress trade reports dated in the last 90 days. They are listed on the BIIB page.

Does this mean BIIB stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Biogen

Everything OQRO holds on this company is on its BIIB page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data